Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Takes Public Comments on Distribution Management Plan for Shionogi’s ADHD Treatment Vyvanse
The Ministry of Health, Labor and Welfare began on December 6 taking public comments on the draft of a “proper distribution management plan” for Shionogi’s pediatric ADHD treatment lisdexamfetamine dimesylate, otherwise known as Vyvanse. The invitation will last through January…
To read the full story
Related Article
- Vyvanse Clears MHLW Panel after a Hold; Approval Expected in March
February 22, 2019
- MHLW Panel OKs Amgen Astellas’ Romosozumab, but ADHD Drug Vyvanse Put on Hold
December 4, 2018
REGULATORY
- MHLW Orders Label Revisions for PPIs, Checkpoint Inhibitors
July 15, 2026
- HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
- CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
- MHLW Urges Stakeholders to Define Essential LLP Information
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…